Aldevron Archives - Medical Design Sourcing

Decoding the future of RNA vaccines with Aldevron’s Venkata Indurthi

[Christoph Burgstedt/Adobe Stock]

From tackling the COVID-19 pandemic to paving the way for future global health challenges, RNA vaccines have rapidly gained attention in recent years. Researchers are already working to extend their capabilities for next-gen medicines. For example, scientists are working to create multivalent RNA formulations that can fight multiple virus variants. They are also exploring AI tools to refine RNA vaccine designs, predicting viral mutations, optimizing dosages and improving stability while easing stringent cold chain requirements. Such considerations could shape future pandemic responses.

In the following Q&A, Venkata Indurthi, chief scientific officer at genomic medicine manufacturing specialist Aldevron gives us an inside look at these RNA vaccine developments. Indurthi details the unique challenges researchers face in developing thermostable formulations, forecasting mutatio…

Prominent cell and gene therapy vendors in 2023

[Image courtesy of catalin/Adobe Stock]

In recent years, the cell and gene therapy market has grown at a rapid clip. The momentum is likely to continue. According to Vision Research Reports, the global cell and gene therapy market size could hit around $42.56 billion by 2030, growing at a CAGR of 39% from 2022 to 2030.

The burgeoning demand in the industry, along with an increasing number of FDA-approved therapies, is also fueling the growth of cell and gene therapy vendors offering tools and services for product development and manufacturing.

The following table includes notable vendors and suppliers active in the call and gene therapy marketplace. This curated selection of companies includes a brief overview of their focus areas.

We have a separate feature focused on companies with prominent cell and gene therapy development efforts.

Company Name Description Notable partnerships Founded He…

Medtech M&A: The industry’s biggest mergers and acquisitions of 2021

[Image from Jp Valery on Unsplash]

Across 2021, medtech has seen a wide range of mergers and acquisitions covering several areas of devices, pharmaceuticals and more.

Some have gone off without a hitch, while others fell into serious scrutiny as mouthwatering financial figures were revealed and major technologies were acquired.

Here are the 10 biggest mergers and acquisitions in medtech in 2021:

Next>>

Danaher to acquire Aldevron for $9.6B

Danaher (NYSE:DHR) announced that it entered into a definitive agreement to acquire Aldevron for approximately $9.6 billion.

Fargo, N.D.-based Aldevron, which employs approximately 600 people, manufactures high-quality plasmid DNA, mRNA and proteins to serve biotechnology and pharmaceutical customers across research, clinical and commercial applications.

Get the full story at our sister site, Pharmaceutical Processing World.

Danaher to acquire Aldevron for $9.6B

Danaher (NYSE:DHR) announced that it entered into a definitive agreement to acquire Aldevron for approximately $9.6 billion.

Fargo, N.D.-based Aldevron, which employs approximately 600 people, manufactures high-quality plasmid DNA, mRNA and proteins to serve biotechnology and pharmaceutical customers across research, clinical and commercial applications.

According to a news release, Aldevron will operate as a standalone operating company and brand within Danaher’s life sciences business segment.

“We are thrilled to have Aldevron join Danaher’s life sciences segment. For nearly 25 years, Aldevron has made tremendous contributions to the advancement of cell, gene and other novel therapies and vaccines,” Danaher president & CEO Rainer M. Blair said in the release. This acquisition will expand our capabilities into the important field of genomic medicine and help us support our customers and their critical mission to bring more li…